Intravenous Pegloticase Market - Regional Analysis
North American Market Insights
North America industry is estimated to dominate majority revenue share of 28% by 2035, as a result of growing prevalence of chronic and refractory gout amid the global population. The market growth in the region is also expected on account of the high prevalence of gout in the adult population. According to researchers, in 2018 there were approximately 13 million prevalent cases of gout were recorded in the United States. This number is expected to rise due to factors like unhealthy lifestyles and the aging population of this region. Additionally, increasing healthcare infrastructure is driving the expansion further in North America. As healthcare facilities like hospitals and clinics enhance their capabilities and accessibility more patients gain access to specialized treatments like intravenous pegloticase. This infrastructure growth in this region translates to improved patient care pathways, streamlined treatment delivery, and better integration of specialty services. Thus, the alignment between rising gout prevalence and the development of healthcare infrastructure is expected to spur the market growth of the intravenous pegloticase market in the North American region.
APAC Market Insights
The Asia Pacific intravenous pegloticase market is estimated to be the second largest share of about ~22% by the end of 2035. The market’s expansion can be attributed majorly to the high product demand due to high growing aging population and increasing incidence of gout in the region. In 2019, there were 16.2 million cases of gout in China, were men and women accounting for 12 million and 4.1 million respectively. Furthermore, studies suggest that estimated gout case counts are high in Asia Pacific regions as there were 6 million cases in East Asia, 7 million cases in South Asia, and 0.6 million cases in Australasia. The increasing prevalence of gout in the region can be attributed to factors such as changes in lifestyle, dietary habits, and an aging population. As the incidence of gout rises there is a growing need for effective treatment like intravenous pegloticase. Thus, driving the intravenous pegloticase market growth of intravenous pegloticase in the region.
